Yep, and I expect those pathways will involve conducting new phase 3 trials costing in the region of $50-$100m each...
Ann: Appendix 4C Quarterly Activity Report, page-80
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.018(1.58%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.12 | $1.989M | 1.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 99236 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 30375 | 13 |
View Market Depth
| Last trade - 10.32am 08/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |